Monahan Wyatt (stevensoap37)

sed on community samples (β [SE] = -1.68 [0.79]; P = .04) or with lower methodological quality (β [SE] = -2.86 [1.30]; P = .03) were associated more strongly with suicide attempts in those reporting experiences of sexual abuse, whereas young age was associated with both suicide attempts (β [SE] = -0.59 [0.27]; P = .03) and ideation (β [SE] = -0.41 [0.18]; P = .03). These findings suggest that policy actions should focus on raising public awareness and offering proactive suicide prevention therapies for children and young adults who have experienced abuse and/or neglect. These findings suggest that policy actions should focus on raising public awareness and offering proactive suicide prevention therapies for children and young adults who have experienced abuse and/or neglect. Reducing unintended pregnancy is a national public health priority. Incentive metrics are increasingly used by health systems to improve health outcomes and reduce costs, but limited data exist on the association of incentive metrics with contraceptive use. To evaluate whether an association exists between implementing an incentive metric and effective contraceptive use within the Oregon Medicaid program. In this state-level, claims-based cohort study, a comparative interrupted time series design was used to evaluate whether the implementation of an effective contraceptive use incentive metric on January 1, 2015, was associated with changes in contraceptive use among Oregon Medicaid adult enrollees when compared with commercially insured women. The participants were adult women at risk of pregnancy (18-50 years of age) living in Oregon from January 1, 2012, through December 31, 2017, and enrolled in Medicaid (532 337 person-years) or in commercial health insurance (1 131 738 person-years). Implementatlly insured comparison group. This finding is relevant given national efforts aimed at adopting a similar metric for widespread use. Implementation of the effective contraceptive use incentive metric was associated with a significant increase in contraceptive use among Medicaid enrollees relative to a commercially insured comparison group. This finding is relevant given national efforts aimed at adopting a similar metric for widespread use. Interpreting randomized clinical trials (RCTs) and their clinical relevance is challenging when P values are either marginally above or below the P = .05 threshold. To use the concept of reverse fragility index (RFI) to provide a measure of confidence in the neutrality of RCT results when assessed from the clinical perspective. In this cross-sectional study, a MEDLINE search was conducted for RCTs published from January 1, 2013, to December 31, 2018, in JAMA, the New England Journal of Medicine (NEJM), and The Lancet. Eligible studies were phase 3 and 4 trials with 11 randomization and statistically nonsignificant binary primary end points. Data analysis was performed from August 1, 2019, to August 31, 2019. Single vs multicenter enrollment, total number of events, private vs government funding, placebo vs active control, and time to event vs frequency data. The primary outcome was the median RFI with interquartile range (IQR) at the P = .05 threshold. Secondary outcomes were the number of RCTs in wt primary end points vs frequency data (9 [5-14] vs 7 [4-13]; P = .43). The median (IQR) RFI at the P = .01 threshold was 12 (7-19) and at the P = .005 threshold was 14 (9-21). This cross-sectional study found that a relatively small number of events (median of 8) had to change to move the primary end point of an RCT from nonsignificant to statistically significant. These findings emphasize the nuance required when interpreting trial results that did not meet prespecified significance thresholds. This cross-sectional study found that a relatively small number of events (median of 8) had to chang